Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial | Zendy

Philip J. Barter | Zendy; KerryAnne Rye | Zendy; JeanClaude Tardif | Zendy; David D. Waters | Zendy; S. Matthijs Boekholdt | Zendy; Andrei Breazna | Zendy; John J.P. Kastelein | Zendy

Open Access

Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A _1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial

Author(s) -

Philip J. Barter,

KerryAnne Rye,

JeanClaude Tardif,

David D. Waters,

S. Matthijs Boekholdt,

Andrei Breazna,

John J.P. Kastelein

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.018259

Subject(s) - cholesterylester transfer protein , atorvastatin , medicine , endocrinology , insulin resistance , insulin , diabetes mellitus , homeostatic model assessment , glucose homeostasis , glycemic , lipoprotein , cholesterol

High-density lipoproteins have antidiabetic properties in vitro. Furthermore, elevated high-density lipoprotein levels accompanying a genetic deficiency of cholesteryl ester transfer protein are associated with decreased levels of plasma glucose. We now investigate effects on glucose homeostasis of inhibiting cholesteryl ester transfer protein with torcetrapib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research